 |
 |

ApoA-1 Milano and Regression of Atherosclerosis
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: Although Dr Nissen and colleagues1 found a 4.2% mean reduction in atheroma, this number is actually substantially less than what has been observed in animal studies. For instance, my colleagues and I reported that a 90-minute infusion of 1 g of recombinant protein in rabbits resulted in a 30% mean reduction of plaque volume.2
I believe, however, that results of these 2 studies are comparable. Although rabbits' atheromatous lesions develop over a few months and comprise nearly 90% free cholesterol-enriched foam cells, this is not the case for human lesions. Such "removable material" (eg, foam cells and cholesterol-enriched debris) represents only 13% to 26% of the material in human plaques, depending on the age or sex of the examined individuals.3-4 Therefore, the 4.2% reduction in human plaque volume approximates the 30% reduction we observed in rabbits. A similar approach in younger individuals with a larger volume of . . . [Full Text of this Article]
Cesare R. Sirtori, MD, PhD
cesare.sirtori@unimi.it Department of Clinical Pharmacology University of Milano Milan, Italy
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial
, , , , , , , , , , , , , and
JAMA. ;290():2292-2300.
FULL TEXT
ApoA-1 Milano and Regression of Atherosclerosis
, , , and
JAMA. ;291():1319-1319.
FULL TEXT
ApoA-1 Milano and Regression of Atherosclerosis--Reply
JAMA. ;291():1320-1320.
FULL TEXT
|